Dimensional Fund Advisors LP Sells 16,017 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Dimensional Fund Advisors LP lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 586,701 shares of the company's stock after selling 16,017 shares during the quarter. Dimensional Fund Advisors LP owned 0.72% of IDEXX Laboratories worth $242,569,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of IDXX. First Trust Advisors LP lifted its position in shares of IDEXX Laboratories by 8.5% during the 4th quarter. First Trust Advisors LP now owns 213,106 shares of the company's stock valued at $88,107,000 after acquiring an additional 16,656 shares during the last quarter. Forum Financial Management LP boosted its position in shares of IDEXX Laboratories by 4.9% in the 4th quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after purchasing an additional 29 shares during the period. Brant Point Investment Management LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth about $4,134,000. Commerce Bank lifted its stake in IDEXX Laboratories by 7.0% during the fourth quarter. Commerce Bank now owns 12,388 shares of the company's stock valued at $5,122,000 after buying an additional 808 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of IDEXX Laboratories by 3.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 73,395 shares of the company's stock worth $30,330,000 after acquiring an additional 2,408 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $3.54 during midday trading on Friday, hitting $437.44. The company had a trading volume of 939,265 shares, compared to its average volume of 631,554. The firm has a fifty day simple moving average of $420.16 and a two-hundred day simple moving average of $429.68. The stock has a market cap of $35.45 billion, a price-to-earnings ratio of 41.00, a P/E/G ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $548.88.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $523.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.